Method of identifying persons with insufficient pharmacological mobilization to obtain HSPC, the human Panx1 gene to be used in the identification of such persons and a kit for identifying such persons
PL429364A1
Animal model of human prostate cancer, method of its production, application of the model, and method of evaluating a therapeutic and/or preventive agent against prostate cancer, and method of testing compounds for their carcinogenicity and/or influencing the prostate cancer progression
PL429126A1
Method of preserving breast milk and breast milk preserved using this method
PL428611A1
Hearing aid
PL427944A1
Urolithine A and composition containing it for external use in inflammation of various etiologies
PL427899A1
Device for taking faeces samples
EP3494955A1
Cosmetic composition for promoting hair growth
WO2018096502A1
Oral compositions comprising beta-escin for reducing acetaldehyde toxicity
PL423146A1
Oleacein intended for application in atherosclerosis prevention
PL423041A1
New crystalline form of anhydrous 17-β-estradiol, method for obtaining it and pharmaceutical composition that contains new crystalline form of anhydrous 17-β-estradiol and its application
PL422741A1
New derivatives of 5-aminotetrazole with antibacterial and antimycotic effects
WO2017212463A1
Methods for diagnosis, differentiation and monitoring using urine proteins as markers in iga nephropathy
PL421423A1
New derivative of N-dimethylisopropylpropane
EP3358355A1
Use of serum 2-cysteine peroxiredoxins (2-cys-prdx) as biomarkers of chronic kidney diseases (ckd) such as lupus nephritis (ln), iga nephropathy (igan) and autosomal-dominant polycystic kidney disease (adpkd) useful for diagnosing, monitoring, and prognosing in these diseases and method of differentiation of these diseases
PL418702A1
Enthezamide-containing pharmaceutical composition in the form of a tablet
PL415730A1
Method for calibration of the middle ear acoustic implant of a patient during tympanoplasty operations and the system for the application of this method
EP3181118A1
Synergistic combination of txnr inhibitors and ascorbate for treatment of b cell malignancies
